Allogene Therapeutics Files Proxy Materials
Ticker: ALLO · Form: DEFA14A · Filed: Apr 30, 2025 · CIK: 1737287
| Field | Detail |
|---|---|
| Company | Allogene Therapeutics, Inc. (ALLO) |
| Form Type | DEFA14A |
| Filed Date | Apr 30, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, shareholder-meeting, regulatory-filing
Related Tickers: ALLO
TL;DR
ALLO proxy filing out, shareholders vote soon.
AI Summary
Allogene Therapeutics, Inc. filed a Definitive Additional Materials (DEFA14A) on April 30, 2025, related to its proxy statement. The filing concerns the company's annual meeting and matters presented for shareholder vote. No fee was required for this filing.
Why It Matters
This filing provides shareholders with essential information regarding the company's upcoming annual meeting and the proposals they will be voting on, impacting corporate governance.
Risk Assessment
Risk Level: low — This is a routine proxy filing providing information to shareholders and does not inherently introduce new financial risks.
Key Players & Entities
- Allogene Therapeutics, Inc. (company) — Registrant
- 0001737287-25-000050.txt (document) — Filing document name
- 20250430 (date) — Filing date
FAQ
What type of filing is this DEFA14A for Allogene Therapeutics?
This is a Definitive Additional Materials filing, indicated by the checkmark next to 'Definitive Additional Materials' and the form type DEFA14A.
When was this filing made?
The filing was made on April 30, 2025.
What is the company's Central Index Key (CIK)?
Allogene Therapeutics, Inc.'s Central Index Key is 0001737287.
What is the company's primary business according to the filing?
The company's Standard Industrial Classification is 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]'.
Was there a fee required for this filing?
No fee was required for this filing, as indicated by the checkmark next to 'No fee required'.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 30, 2025 regarding Allogene Therapeutics, Inc. (ALLO).